A Niemann-Pick disease genetic test looks for disease-causing variants in SMPD1, NPC1, or NPC2, but these genes do not all cause the same disorder. Biallelic variants in SMPD1 cause acid sphingomyelinase deficiency, historically called Niemann-Pick disease types A, A/B, and B. Biallelic variants in NPC1 or NPC2 cause Niemann-Pick disease type C, a separate lysosomal disorder that disrupts intracellular lipid transport. Genetic testing may confirm a suspected diagnosis, clarify an abnormal enzyme or biomarker result, identify relatives who are carriers, or support reproductive planning. The result must be interpreted alongside symptoms, family history, biochemical testing, and the laboratory’s methods. A positive result can establish the molecular diagnosis when the correct number and type of pathogenic variants are found. A negative result lowers risk but may not exclude disease, especially when testing was limited. A variant of uncertain significance is not a diagnosis and should not guide major medical or reproductive decisions by itself.
- SMPD1 testing evaluates acid sphingomyelinase deficiency; NPC1 and NPC2 testing evaluates Niemann-Pick disease type C.
- Most affected people have two pathogenic variants in the same disease-associated gene because these conditions are usually autosomal recessive.
- One pathogenic variant usually indicates carrier status, not an affected diagnosis.
- No fasting is normally required; testing usually uses blood, saliva, or a cheek-swab sample.
- A negative result may need follow-up with deletion/duplication analysis, enzyme testing, biomarkers, or broader sequencing.
- Newborn cholestasis, breathing difficulty, loss of skills, swallowing problems, seizures, or rapid neurologic decline require prompt specialist assessment.
Table of Contents
- What the Test Evaluates
- When Testing Is Considered
- Genes, Inheritance, and Disease Types
- How the Testing Process Works
- Understanding Genetic Test Results
- Accuracy, Limitations, and Follow-Up
- Family and Reproductive Implications
- What Happens After Diagnosis
What the Test Evaluates
A Niemann-Pick disease genetic test examines DNA for variants that interfere with one of three lysosomal genes. Lysosomes are cell structures that break down and recycle fats and other materials. When a relevant gene does not work correctly, specific lipids accumulate in cells and can damage the liver, spleen, lungs, brain, nerves, bone marrow, or other tissues.
The label “Niemann-Pick disease” can be confusing because it covers two biologically different groups:
| Gene | Current disorder name | Historical terminology | Main cellular problem |
|---|---|---|---|
| SMPD1 | Acid sphingomyelinase deficiency (ASMD) | Niemann-Pick types A, A/B, and B | Low acid sphingomyelinase activity causes sphingomyelin accumulation |
| NPC1 | Niemann-Pick disease type C1 | Niemann-Pick type C | Impaired movement of cholesterol and other lipids inside cells |
| NPC2 | Niemann-Pick disease type C2 | Niemann-Pick type C | Impaired lysosomal lipid transport |
The test is usually a single-gene genetic test when clinical findings strongly point to one disorder. A multigene lysosomal-storage or neurodegeneration panel may be more efficient when symptoms overlap several conditions. Exome or genome sequencing may be considered when targeted testing does not explain a strong clinical suspicion.
Genetic testing is different from biochemical testing. For ASMD, acid sphingomyelinase enzyme activity helps show whether the enzyme is deficient. For type C, plasma biomarkers such as oxysterols, lysosphingomyelin-related compounds, and bile-acid metabolites may support suspicion. Genetic testing identifies the underlying DNA cause, which is especially useful for confirming inheritance, testing relatives, and planning future pregnancies.
When Testing Is Considered
Testing may be ordered for an affected child or adult, an apparently healthy relative, a reproductive partner, or a pregnancy. The best test depends on why it is being requested.
Symptoms that can prompt diagnostic testing
ASMD often causes enlarged liver and spleen, low platelets, abnormal lipids, poor growth, interstitial lung disease, and reduced bone density. Severe infantile neurovisceral ASMD can also cause developmental plateau or regression, low muscle tone, feeding difficulty, and a cherry-red spot in the retina. Chronic visceral ASMD may appear later and may have little or no central nervous system involvement.
Type C varies widely by age. Newborns may have prolonged jaundice, cholestasis, enlarged liver and spleen, fluid accumulation, or respiratory disease. Children may develop clumsiness, ataxia, declining school performance, speech changes, seizures, dystonia, sudden loss of muscle tone triggered by laughter, or difficulty moving the eyes vertically. Teenagers and adults may first show psychiatric symptoms, cognitive decline, balance problems, swallowing difficulty, or an unusual movement disorder.
No single symptom proves Niemann-Pick disease. Similar findings occur in other lysosomal storage diseases, liver disorders, leukodystrophies, mitochondrial conditions, hereditary ataxias, and acquired illnesses. A carefully chosen genetic panel test can reduce the chance of missing another gene when the presentation is not specific.
Family history and carrier testing
Testing is also appropriate when a relative has a confirmed pathogenic variant. In that setting, targeted testing for the known family variant is usually faster, less expensive, and easier to interpret than sequencing the full gene. Healthy siblings of an affected person may want testing before having children. Adult children of known carriers may also request testing.
Carrier screening may identify SMPD1, NPC1, or NPC2 variants in people without symptoms. A carrier result should be confirmed and interpreted in the context of the laboratory’s detection rate and the partner’s result. General carrier screening test principles apply, but gene-specific limitations still matter.
Prenatal and newborn settings
Prenatal diagnosis can be offered when both disease-causing variants in a family are known. Testing may use chorionic villus sampling or amniocentesis. Preimplantation genetic testing for monogenic disease may also be available with in vitro fertilization. These options require advance planning because the familial variants and laboratory strategy should be established before a pregnancy whenever possible.
Some newborn screening programs evaluate ASMD, but availability differs by country and region. An abnormal screen is not a diagnosis. It needs rapid confirmatory enzyme and molecular testing, ideally through a metabolic genetics center. Routine newborn screening for type C is not universal.
Genes, Inheritance, and Disease Types
SMPD1, NPC1, and NPC2 disorders usually follow autosomal recessive inheritance. An affected person generally has two clinically significant variants in the same gene, one inherited from each biological parent. The variants may be identical or different.
When both parents carry a pathogenic variant in the same gene, each pregnancy has:
- a 25% chance of an affected child with two variants;
- a 50% chance of a carrier child with one variant; and
- a 25% chance of a child who inherited neither family variant.
These probabilities reset with every pregnancy. They do not change based on the sex of the child or the outcomes of previous pregnancies. A fuller explanation of this pattern appears in autosomal recessive genetic testing guidance.
SMPD1 and the ASMD spectrum
SMPD1 provides instructions for acid sphingomyelinase. Very low enzyme activity leads to sphingomyelin accumulation. Disease severity exists on a continuum rather than in perfectly separated categories.
- Infantile neurovisceral ASMD, historically type A, begins early and includes severe neurologic decline.
- Chronic neurovisceral ASMD, historically type A/B, includes visceral disease with variable neurologic involvement.
- Chronic visceral ASMD, historically type B, more often affects the liver, spleen, lungs, blood counts, lipids, bones, and growth, with little or no classic neurodegeneration.
Some SMPD1 variants have known associations with milder or more severe disease, but genotype does not predict every feature. Residual enzyme activity, the combination of variants, other genes, treatment, and individual biology can alter the course.
NPC1 and NPC2
NPC1 and NPC2 proteins work together in the movement of cholesterol and related lipids out of lysosomes. Most type C cases result from NPC1 variants; NPC2 accounts for a smaller proportion. Both genes can produce a broad range from severe neonatal disease to adult-onset neurologic or psychiatric illness.
Age at neurologic onset often relates more closely to the rate of progression than the age at which liver or spleen findings first appeared. Two people with the same gene—and sometimes the same variants—can still differ meaningfully. A DNA report should therefore support diagnosis and family testing, not be treated as a precise forecast of lifespan, disability, or treatment response.
A variant that arises for the first time in a child is possible but uncommon in a recessive condition. Other explanations for an unexpected family pattern include parental mosaicism, a deletion missed by routine sequencing, incorrect biological relationships, or a variant that was initially misclassified.
How the Testing Process Works
Most tests use a blood sample because it usually provides reliable DNA and can be collected alongside enzyme or biomarker studies. Saliva and cheek swabs are acceptable for many genetic assays, although low DNA yield, food contamination, recent transfusion, or sample mix-ups can occasionally require recollection. Prenatal testing uses placental tissue or amniotic fluid collected by a specialist.
No fasting, medication pause, or exercise restriction is normally needed for DNA testing. Biochemical tests may have their own specimen and handling rules, so the ordering team should follow the laboratory’s instructions.
Common laboratory methods
Sequence analysis reads the coding regions and nearby splice boundaries of a gene. It detects many missense, nonsense, splice-site, and small insertion or deletion variants. It may not detect a deletion of one or more exons, a complex rearrangement, a deep intronic variant, low-level mosaicism, or a change in a poorly covered region.
Deletion/duplication analysis looks for missing or extra gene segments that sequence analysis may not identify. The added yield varies by gene. A laboratory may perform it automatically or only after sequencing finds one or no pathogenic variants.
Targeted familial-variant testing checks only the known change in a family. It is highly efficient for relatives but does not assess the rest of the gene. A person can rarely carry another unrelated pathogenic variant that targeted testing would not detect.
Multigene panels evaluate many disorders with overlapping symptoms. Panel content and technical sensitivity differ among laboratories. The report should state which genes, exons, copy-number changes, and variant types were assessed.
Exome or genome sequencing can help when targeted studies are negative or the clinical picture is atypical. Exome sequencing focuses mainly on protein-coding regions. Genome sequencing covers more noncoding DNA and may detect a broader range of structural changes, although interpretation remains challenging.
For ASMD, low acid sphingomyelinase activity is an important part of confirming an affected diagnosis. For type C, modern diagnostic pathways often combine biomarkers with NPC1 and NPC2 sequencing. Older cell-based cholesterol-staining studies may still be used in selected unresolved cases, but they are no longer the first test in many centers.
Turnaround time commonly ranges from about two to eight weeks, depending on the laboratory, test breadth, urgency, and whether family samples are needed. Prenatal and critically ill infant testing may follow accelerated workflows.
Understanding Genetic Test Results
A useful interpretation begins with four questions: Which gene was tested? How many relevant variants were found? How did the laboratory classify them? Do the findings fit the person’s biochemical and clinical picture?
| Result | Usual interpretation | Typical next step |
|---|---|---|
| Two pathogenic or likely pathogenic variants in the same gene | Supports or establishes an affected molecular diagnosis when the variants are on opposite chromosome copies | Confirm phase if needed, correlate with biochemical findings, and arrange specialist care |
| One pathogenic or likely pathogenic variant | Usually carrier status; may be incomplete testing in a symptomatic person | Consider deletion/duplication analysis, broader testing, enzyme or biomarker studies, and family testing |
| No pathogenic variant found | Risk is reduced but disease may not be excluded | Review coverage, methods, phenotype, and alternative diagnoses |
| Variant of uncertain significance | Evidence is insufficient to call the variant disease-causing or benign | Do not use alone for diagnosis or reproductive decisions; seek periodic reinterpretation |
| Benign or likely benign variant | Not considered an explanation for disease | No disease-specific action based on that variant |
Positive affected result
Two pathogenic or likely pathogenic variants in SMPD1 support ASMD; two in NPC1 or NPC2 support type C. The laboratory may need parental testing to show that the two variants are in trans, meaning one came from each parent. If both variants are on the same chromosome copy, the other copy may still be normal, so the result may represent carrier status rather than disease.
A molecular result should fit the phenotype. For ASMD, clinicians generally expect deficient enzyme activity. A discordant result may reflect sample error, variant interpretation uncertainty, pseudodeficiency, another diagnosis, or an unusual mechanism that needs specialist review.
Carrier result
One pathogenic variant usually means the person is a carrier. Carriers are generally not expected to develop classic recessive Niemann-Pick disease. Research has examined subtle findings in some NPC1 heterozygotes, but evidence does not support treating a typical carrier result as a diagnosis of type C.
Carrier risk for children depends on the other biological parent. If the partner tests negative, the chance of an affected child becomes much lower but is not zero because no test detects every possible pathogenic variant. If both partners carry variants in the same gene, reproductive counseling is recommended.
Negative result
“Negative” means the laboratory did not identify a reportable pathogenic or likely pathogenic variant using the methods performed. It does not necessarily mean the person has no genetic condition. Residual risk is higher when symptoms strongly fit the disease, only common variants were tested, copy-number analysis was omitted, or the familial variant is unknown.
Variant of uncertain significance
A VUS should not be treated as positive. Laboratories use population frequency, computer prediction, functional studies, family segregation, case reports, and other evidence to classify variants. Evidence can change, so a VUS may later be upgraded or downgraded. Testing affected and unaffected relatives can sometimes help, but only when a genetics professional determines that segregation information would be informative. The broader VUS result framework is especially important in rare-disease panels, where uncertain findings are common.
Accuracy, Limitations, and Follow-Up
Clinical DNA sequencing is analytically accurate for the regions it reads well, but diagnostic accuracy depends on more than the machine. A technically correct result can still be clinically incomplete if the wrong gene was chosen, a structural change was not assessed, or the person has another disorder with similar symptoms.
Important limitations include:
- incomplete coverage of certain exons or GC-rich regions;
- deep intronic and regulatory variants not included in standard analysis;
- exon-level or whole-gene deletions and duplications missed by sequence-only testing;
- complex rearrangements or repeat-rich regions that are difficult to map;
- low-level mosaicism below the assay’s detection threshold;
- newly discovered disease mechanisms not yet included in interpretation databases;
- uncertain phase when two variants are found without parental samples; and
- variant classifications that may change as evidence grows.
For a symptomatic person with one SMPD1 variant, acid sphingomyelinase activity and deletion/duplication testing can be particularly helpful. For suspected type C with negative or incomplete molecular findings, specialists may review biomarkers, request broader sequencing, examine copy-number data, test parental samples, or consider specialized functional studies.
A negative panel may justify whole-exome sequencing or genome sequencing when the clinical picture remains unexplained. Reanalysis after one to three years can identify diagnoses that were missed before a gene-disease association or variant interpretation became established.
Before acting on a consumer DNA result, confirm it in a certified clinical laboratory. Direct-to-consumer genotyping often checks only selected variants and can produce false positives, false reassurance, or ancestry-dependent gaps. Medical decisions should use a validated report tied to the correct person and specimen.
Family and Reproductive Implications
A confirmed result can clarify risk for siblings, parents, children, aunts, uncles, and cousins. The most informative person to test first is usually an affected relative. Once the familial variants are known, relatives can receive targeted testing rather than a broad, less focused screen.
Parents of an affected child are usually carriers. Full siblings have a 25% chance of being affected, a 50% chance of being carriers, and a 25% chance of inheriting neither variant. An unaffected sibling’s chance of being a carrier is therefore 2 in 3 after affected status has been excluded. Adult-onset testing and testing of minors should be considered differently: carrier testing in children is often deferred when it has no immediate medical benefit, while diagnostic testing should not be delayed when a child has concerning symptoms.
Reproductive options may include:
- natural conception with prenatal diagnosis;
- in vitro fertilization with preimplantation genetic testing for the known familial variants;
- use of donor egg, donor sperm, or donor embryo;
- adoption; or
- natural conception without fetal testing.
No single option is medically or personally right for every family. Genetic counseling should explain detection limits, procedure timing, miscarriage risks associated with diagnostic sampling, possible uncertain results, costs, and the values of the people involved. Information about prenatal genetic testing can help distinguish screening from definitive fetal diagnosis.
Testing should also account for reproductive partners from all ancestry groups. Although certain SMPD1 variants are more frequent in some populations, relying only on ancestry can miss carriers. Pan-ethnic sequencing generally provides broader coverage than a small ancestry-based mutation panel.
Privacy, insurance, and employment protections vary by country and may not cover life, disability, or long-term-care insurance. A genetics professional can discuss local rules before testing, particularly for an unaffected adult.
What Happens After Diagnosis
A confirmed diagnosis should lead to coordinated care with a metabolic geneticist or lysosomal disease center. Genetic results alone do not show the current amount of organ damage, so the initial evaluation usually includes clinical examination and targeted studies of affected systems.
For ASMD, assessment may include blood counts, liver enzymes and synthetic function, lipid profile, lung function, chest imaging, spleen and liver volume, growth and nutrition, bone density, eye examination, and neurologic or developmental review. Enzyme replacement therapy with olipudase alfa treats non-central-nervous-system manifestations in eligible people, but it does not cross the blood-brain barrier enough to correct the neurodegeneration of infantile neurovisceral disease. Treatment choice and dosing belong with an experienced specialist.
For type C, care often includes neurologic examination, vertical eye-movement assessment, swallowing and nutrition evaluation, hearing testing, developmental or cognitive assessment, psychiatric care when needed, mobility and fall-risk review, seizure management, and liver or lung evaluation based on age and symptoms. Disease-modifying therapy availability and approved indications differ by country and can change, so families should receive current advice from a specialty center.
Supportive treatment can be as important as disease-specific therapy. Physical, occupational, speech, feeding, respiratory, educational, psychological, and palliative services may preserve function and comfort. Swallowing problems deserve early attention because aspiration can cause pneumonia and may contribute to serious decline.
Urgent medical assessment is warranted for breathing difficulty, blue or gray color, severe dehydration, repeated choking, suspected aspiration, prolonged seizure, sudden loss of consciousness, rapidly worsening jaundice, major bleeding, severe abdominal pain after trauma in a person with an enlarged spleen, or a marked new loss of skills.
Relatives should receive a written family letter or clear summary stating the gene, exact variant notation, inheritance pattern, and recommended test. Keeping the original laboratory report matters because gene names, transcript numbers, and variant descriptions prevent errors during future testing. Families should also ask whether the laboratory offers automatic reclassification notices or whether they need to request periodic review.
A molecular diagnosis can end a long diagnostic search, but it is also the beginning of individualized care. The most useful result is one connected to biochemical confirmation when appropriate, careful phenotype assessment, family testing, and a plan that addresses both current health needs and future reproductive choices.
References
- Niemann-Pick Disease Type C 2025 (Review)
- Acid Sphingomyelinase Deficiency 2023 (Review)
- 2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C 2026 (Guideline)
- The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann-Pick Disease: A Comprehensive Review 2024 (Review)
- Understanding the phenotypic variability in Niemann-Pick disease type C (NPC): a need for precision medicine 2023 (Review)
Disclaimer
This article provides general information about Niemann-Pick disease genetic testing and does not replace evaluation by a metabolic specialist, geneticist, or genetic counselor. Test methods, variant classifications, treatment approvals, and reproductive options vary by laboratory and location. Seek urgent medical care for severe breathing problems, prolonged seizures, major bleeding, rapidly worsening jaundice, or sudden neurologic decline.
